Investing.com UK - Financial Markets Worldwide

JELD-WEN Likely To Post Lower Q2 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

Published 07/08/2023, 14:16
Updated 07/08/2023, 15:40
© Reuters. JELD-WEN Likely To Post Lower Q2 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

Benzinga - JELD-WEN Holding, Inc. (NYSE: JELD) is expected to report its second quarter financial results, after the closing bell on Aug. 7, 2023.

Analysts expect the company to post quarterly earnings at 33 cents per share, down from year-ago earnings of 57 cents per share. The company’s revenue might come in at $1.1 billion, compared to year-ago sales of $1.33 billion.

JELD-WEN shares rose 1.6% to close at $17.99 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

  • Jefferies analyst Philip Ng maintained a Hold rating and raised the price target from $15 to $18 on July 13, 2023. This analyst has an accuracy rate of 69%.
  • Truist Securities analyst Keith Hughes maintained a Hold rating and increased the price target from $12 to $15 on May 11, 2023. This analyst has an accuracy rate of 78%.
  • B. Riley Securities analyst Alex Rygiel maintained a Neutral rating and boosted the price target from $12 to $14 on Feb. 22, 2023. This analyst has an accuracy rate of 83%.
  • Deutsche Bank analyst Joe Ahlersmeyer maintained a Hold rating and increased the price target from $11 to $12 on Jan. 11, 2023. This analyst has an accuracy rate of 68%.
  • JP Morgan analyst Michael Rehaut upgraded the stock from Underweight to Neutral with a price target of $9.5 on Dec. 20, 2022. This analyst has an accuracy rate of 73%.

Read This Next: Top 5 Health Care Stocks That Could Blast Off In August

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.